Ginsenoside Rd regulates the Akt/mTOR/p70S6K signaling cascade and suppresses angiogenesis and breast tumor growth

Zhang,Eryun; Shi,Hailian; Yang,Li; Wu,Xiaojun; Wang,Zhengtao

doi:10.3892/or.2017.5652

Ginsenoside Rd regulates the Akt/mTOR/p70S6K signaling cascade and suppresses angiogenesis and breast tumor growth

Authors:
- Eryun Zhang
- Hailian Shi
- Li Yang
- Xiaojun Wu
- Zhengtao Wang
View Affiliations

Affiliations: Shanghai Key Laboratory of Complex Prescriptions, The Ministry of Education (MOE) Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, P.R. China
Published online on: May 19, 2017 https://doi.org/10.3892/or.2017.5652
Pages: 359-367

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Blockade of angiogenesis is an important approach for cancer treatment and prevention. In the present study, we investigated the effect of ginsenoside Rd (Rd) on angiogenesis in vitro and in vivo. Our results demonstrated that Rd inhibited vascular endothelial growth factor (VEGF)-induced migration, tube formation and proliferation of primary cultured human umbilical vascular endothelial cells (HUVECs) dose‑dependently. Furthermore, Rd abrogated VEGF-induced sprouting of the vessels from aortic rings, and inhibited vascular formation in the Matrigel plug assay in vivo. Under normoxic or hypoxic conditions, Rd suppressed VEGF‑induced activation of Akt/mammalian target of rapamycin (mTOR) signaling transduction cascades in HUVECs. When intraperitoneally administered to mice bearing human breast cancer (MDA‑MB-231) cell xenografts, Rd significantly decreased the volume and the weight of solid tumors in a dose-dependent manner, and decreased tumor angiogenesis as less Ki67- and CD31-positive cells were found. Additionally, we found that Rd inhibited proliferation and induced apoptosis as well as the inhibition of Akt/mTOR/P70S6 kinase signaling in breast cancer cells. Collectively, our findings revealed that Rd may be a promising anti-angiogenic drug with significant antitumor activity in human breast cancer.

View Figures

View References

1	Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995. View Article : Google Scholar : PubMed/NCBI
2	Potente M, Gerhardt H and Carmeliet P: Basic and therapeutic aspects of angiogenesis. Cell. 146:873–887. 2011. View Article : Google Scholar : PubMed/NCBI
3	Gao W, Chang G, Wang J, Jin W, Wang L, Lin Y, Li H, Ma L, Li Q and Pang T: Inhibition of K562 leukemia angiogenesis and growth by selective Na+/H+ exchanger inhibitor cariporide through down-regulation of pro-angiogenesis factor VEGF. Leuk Res. 35:1506–1511. 2011. View Article : Google Scholar : PubMed/NCBI
4	Otrock ZK, Mahfouz RA, Makarem JA and Shamseddine AI: Understanding the biology of angiogenesis: Review of the most important molecular mechanisms. Blood Cells Mol Dis. 39:212–220. 2007. View Article : Google Scholar : PubMed/NCBI
5	Thairu N, Kiriakidis S, Dawson P and Paleolog E: Angiogenesis as a therapeutic target in arthritis in 2011: Learning the lessons of the colorectal cancer experience. Angiogenesis. 14:223–234. 2011. View Article : Google Scholar : PubMed/NCBI
6	Weis SM and Cheresh DA: Tumor angiogenesis: Molecular pathways and therapeutic targets. Nat Med. 17:1359–1370. 2011. View Article : Google Scholar : PubMed/NCBI
7	Folkman J: Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov. 6:273–286. 2007. View Article : Google Scholar : PubMed/NCBI
8	Adams RH and Alitalo K: Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol. 8:464–478. 2007. View Article : Google Scholar : PubMed/NCBI
9	Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ and Holash J: Vascular-specific growth factors and blood vessel formation. Nature. 407:242–248. 2000. View Article : Google Scholar : PubMed/NCBI
10	Jiang BH: PI3K/AKT and mTOR/p70S6K1 signaling pathways in human cancer. Curr Cancer Drug Targets. 13:2332013. View Article : Google Scholar : PubMed/NCBI
11	Jiang BH and Liu LZ: AKT signaling in regulating angiogenesis. Curr Cancer Drug Targets. 8:19–26. 2008. View Article : Google Scholar : PubMed/NCBI
12	Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT and De Bruijn EA: Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 56:549–580. 2004. View Article : Google Scholar : PubMed/NCBI
13	Chen CF, Chiou WF and Zhang JT: Comparison of the pharmacological effects of Panax ginsengPanax quinquefolium. Acta Pharmacol Sin. 29:1103–1108. 2008. View Article : Google Scholar : PubMed/NCBI
14	Ng TB: Pharmacological activity of sanchi ginseng (Panax notoginseng). J Pharm Pharmacol. 58:1007–1019. 2006. View Article : Google Scholar : PubMed/NCBI
15	Christensen LP: Ginsenosides chemistry, biosynthesis, analysis, and potential health effects. Adv Food Nutr Res. 55:1–99. 2009. View Article : Google Scholar : PubMed/NCBI
16	Xie Z, Shi M, Zhang C, Zhao H, Hui H and Zhao G: Ginsenoside Rd protects against cerebral ischemia-reperfusion injury via decreasing the expression of the NMDA receptor 2B subunit and its phosphorylated product. Neurochem Res. 41:2149–2159. 2016. View Article : Google Scholar : PubMed/NCBI
17	Zeng X, Li J and Li Z: Ginsenoside Rd mitigates myocardial ischemia-reperfusion injury via Nrf2/HO-1 signaling pathway. Int J Clin Exp Med. 8:14497–14504. 2015.PubMed/NCBI
18	Kim BJ: Involvement of melastatin type transient receptor potential 7 channels in ginsenoside Rd-induced apoptosis in gastric and breast cancer cells. J Ginseng Res. 37:201–209. 2013. View Article : Google Scholar : PubMed/NCBI
19	Lee SY, Kim GT, Roh SH, Song JS, Kim HJ, Hong SS, Kwon SW and Park JH: Proteome changes related to the anti-cancer activity of HT29 cells by the treatment of ginsenoside Rd. Pharmazie. 64:242–247. 2009.PubMed/NCBI
20	Yang ZG, Sun HX and Ye YP: Ginsenoside Rd from Panax notoginseng is cytotoxic towards HeLa cancer cells and induces apoptosis. Chem Biodivers. 3:187–197. 2006. View Article : Google Scholar : PubMed/NCBI
21	Park HJ, Zhang Y, Georgescu SP, Johnson KL, Kong D and Galper JB: Human umbilical vein endothelial cells and human dermal microvascular endothelial cells offer new insights into the relationship between lipid metabolism and angiogenesis. Stem Cell Rev. 2:93–102. 2006. View Article : Google Scholar : PubMed/NCBI
22	Yi T, Yi Z, Cho SG, Luo J, Pandey MK, Aggarwal BB and Liu M: Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res. 68:1843–1850. 2008. View Article : Google Scholar : PubMed/NCBI
23	Nicosia RF and Ottinetti A: Modulation of microvascular growth and morphogenesis by reconstituted basement membrane gel in three-dimensional cultures of rat aorta: A comparative study of angiogenesis in matrigel, collagen, fibrin, and plasma clot. In Vitro Cell Dev Biol. 26:119–128. 1990. View Article : Google Scholar : PubMed/NCBI
24	Malinda KM: In vivo Matrigel migration and angiogenesis assay. Methods Mol Biol. 467:287–294. 2009. View Article : Google Scholar : PubMed/NCBI
25	Gasparini G, Longo R, Toi M and Ferrara N: Angiogenic inhibitors: A new therapeutic strategy in oncology. Nat Clin Pract Oncol. 2:562–577. 2005. View Article : Google Scholar : PubMed/NCBI
26	Fujii T, Yonemitsu Y, Onimaru M, Inoue M, Hasegawa M, Kuwano H and Sueishi K: VEGF function for upregulation of endogenous PlGF expression during FGF-2-mediated therapeutic angiogenesis. Atherosclerosis. 200:51–57. 2008. View Article : Google Scholar : PubMed/NCBI
27	Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
28	Hay N and Sonenberg N: Upstream and downstream of mTOR. Genes Dev. 18:1926–1945. 2004. View Article : Google Scholar : PubMed/NCBI
29	Liu S, Wu P, Ye D, Huang Y, Zhou X, Li Y and Cai L: Effects of lipoxin A4 on CoCl2-induced angiogenesis and its possible mechanisms in human umbilical vein endothelial cells. Pharmacology. 84:17–23. 2009. View Article : Google Scholar : PubMed/NCBI
30	Loboda A, Jazwa A, Wegiel B, Jozkowicz A and Dulak J: Heme oxygenase-1-dependent and -independent regulation of angiogenic genes expression: Effect of cobalt protoporphyrin and cobalt chloride on VEGF and IL-8 synthesis in human microvascular endothelial cells. Cell Mol Biol. 51:347–355. 2005.PubMed/NCBI
31	Ferrara N and Kerbel RS: Angiogenesis as a therapeutic target. Nature. 438:967–974. 2005. View Article : Google Scholar : PubMed/NCBI
32	Reuben SC, Gopalan A, Petit DM and Bishayee A: Modulation of angiogenesis by dietary phytoconstituents in the prevention and intervention of breast cancer. Mol Nutr Food Res. 56:14–29. 2012. View Article : Google Scholar : PubMed/NCBI
33	Holash J, Wiegand SJ and Yancopoulos GD: New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene. 18:5356–5362. 1999. View Article : Google Scholar : PubMed/NCBI
34	Lamalice L, Le Boeuf F and Huot J: Endothelial cell migration during angiogenesis. Circ Res. 100:782–794. 2007. View Article : Google Scholar : PubMed/NCBI
35	Stotz M, Gerger A, Haybaeck J, Kiesslich T, Bullock MD and Pichler M: Molecular targeted therapies in hepatocellular carcinoma: Past, present and future. Anticancer Res. 35:5737–5744. 2015.PubMed/NCBI
36	Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, et al: VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 99:11393–11398. 2002. View Article : Google Scholar : PubMed/NCBI
37	Ferrara N: Vascular endothelial growth factor as a target for anticancer therapy. Oncologist. 9 Suppl 1:S2–S10. 2004. View Article : Google Scholar
38	Noble ME, Endicott JA and Johnson LN: Protein kinase inhibitors: Insights into drug design from structure. Science. 303:1800–1805. 2004. View Article : Google Scholar : PubMed/NCBI
39	Radisavljevic Z: AKT as locus of cancer angiogenic robustness and fragility. J Cell Physiol. 228:21–24. 2013. View Article : Google Scholar : PubMed/NCBI
40	Ciuffreda L, Di Sanza C, Incani UC and Milella M: The mTOR pathway: A new target in cancer therapy. Curr Cancer Drug Targets. 10:484–495. 2010. View Article : Google Scholar : PubMed/NCBI
41	Liu LZ, Zheng JZ, Wang XR and Jiang BH: Endothelial p70 S6 kinase 1 in regulating tumor angiogenesis. Cancer Res. 68:8183–8188. 2008. View Article : Google Scholar : PubMed/NCBI
42	Bhushan S, Kumar A, Malik F, Andotra SS, Sethi VK, Kaur IP, Taneja SC, Qazi GN and Singh J: A triterpenediol from Boswellia serrata induces apoptosis through both the intrinsic and extrinsic apoptotic pathways in human leukemia HL-60 cells. Apoptosis. 12:1911–1926. 2007. View Article : Google Scholar : PubMed/NCBI